Transgene to trial immuno-oncology combination as first-line cancer therapy

France's Transgene (Euronext: TNG) and Bristol-Myers Squibb (NYSE: BMY) are upgrading their clinical research collaboration to test a new immuno-oncological therapy combination as a first-line lung cancer treatment.

The therapy is being evaluated as a potential treatment for advanced non-small cell lung cancer (NSCLC) in certain patient types.

Transgene, which has been working with Bristol-Myers to develop the therapy as a second-line treatment, is hoping to access the larger first-line market for its cancer vaccine.